Key Points
- Biomerica Vice Chairman Allen Barbieri purchased 20,000 shares at $1.60 each, investing $32,000 and increasing his direct ownership by 37.35% to 73,542 shares.
- BMRA shares opened at $2.10, with a market capitalization of approximately $6.49 million and a 52-week trading range of $1.45 to $3.24.
- Analyst sentiment remains negative, with an average rating of “Sell,” although Citizens JMP initiated coverage with a “Market Outperform” rating and a $9 price target; BlackRock also recently acquired a 0.60% stake.
Biomerica, Inc. (NASDAQ:BMRA - Get Free Report) Director David Moatazedi acquired 10,000 shares of Biomerica stock in a transaction dated Wednesday, August 26th. The shares were bought at an average price of $1.60 per share, with a total value of $16,000.00. Following the transaction, the director directly owned 40,625 shares in the company, valued at approximately $65,000. The trade was a 32.65% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Biomerica Trading Up 24.3%
Shares of Biomerica stock opened at $2.10 on Friday. The company has a fifty day simple moving average of $1.66 and a 200-day simple moving average of $1.99. The stock has a market cap of $6.49 million, a price-to-earnings ratio of -2.36 and a beta of 0.35. Biomerica, Inc. has a 12-month low of $1.45 and a 12-month high of $3.24.
Analysts Set New Price Targets
Several equities analysts have issued reports on the stock. Weiss Ratings downgraded shares of Biomerica from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, June 5th. Citizens Jmp assumed coverage on Biomerica in a research report on Tuesday, May 5th. They set a "mkt outperform" rating and a $9.00 target price on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of "Sell" and a consensus target price of $9.00.
View Our Latest Report on Biomerica
Institutional Investors Weigh In On Biomerica
An institutional investor recently bought a new stake in Biomerica stock. BlackRock Inc. acquired a new stake in Biomerica, Inc. (NASDAQ:BMRA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 18,636 shares of the company's stock, valued at approximately $33,000. BlackRock Inc. owned 0.60% of Biomerica at the end of the most recent quarter. Institutional investors and hedge funds own 22.28% of the company's stock.
Biomerica Company Profile
(
Get Free Report)
Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company's product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica's diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.
Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
